ProCE Banner Activity

Emerging Long-Acting ART Regimens for HIV Treatment and Prevention

Slideset Download
View these slides for an expert overview of long-acting agents and formulations currently under investigation for HIV treatment and pre-exposure prophylaxis.

Released: June 14, 2022

Expiration: June 13, 2023

No longer available for credit.

Share

Faculty

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Yvonne Gilleece

Yvonne Gilleece, MB BCh, BAO, FRCP

Honorary Clinical Professor and Consultant in HIV Medicine & Sexual Health
Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust
Chair of the British HIV Association
Lead for HIV & Women
Lead for HIV & Hepatitis
Brighton, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Program Director Disclosure

Program Director

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consultant/advisor/speaker fees from Gilead Sciences, GlaxoSmithKline, J&J, and ViiV.

Faculty Disclosure

Primary Author

Yvonne Gilleece, MB BCh, BAO, FRCP

Honorary Clinical Professor and Consultant in HIV Medicine & Sexual Health
Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust
Chair of the British HIV Association
Lead for HIV & Women
Lead for HIV & Hepatitis
Brighton, United Kingdom

Yvonne Gilleece, MB, BCh, BAO, has disclosed that she has received payment for educational meetings from ViiV, advisory board fees from Gilead Sciences and ViiV, and conference sponsorship from Gilead Sciences.